Gastrointestinal Therapeutics in Asia-Pacific Market Size, Trend and Analysis Report 2019: Radiant Insights, Inc

GBI Research, the leading business intelligence provider, has released its latest research, “Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need”, which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia.

The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

 

Read Complete Report with TOC @ http://www.radiantinsights.com/research/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need

 

Scope

– Disease overview and treatment usage patterns

– Market size and forecast for IBS, UC and CD in APAC market from 2012 to 2019

– Major marketed products for the indications types covered

– In-depth pipeline analysis for IBS, UC and CD

– Key drivers and restraints that have had and are expected to have a significant impact upon the market

– Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

– Align your product portfolio to the markets with high growth potential

– Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth

– Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market

– Develop key strategic initiatives based upon an understanding of key focus areas and leading companies

– Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Advertisements

Hepatitis C Therapeutics in Major Developed Market Size, Share and Forecast Report 2019: Radiant Insights, Inc

GBI Research, has released the pharma report, “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”.

The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales.

View Full Report with TOC @ http://www.radiantinsights.com/research/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape

However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy.

In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients.

As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion.

Scope

– A brief introduction to hepatitis C, including the disease’s pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms.

– In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy.

– A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target.

– In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.

– Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain.

– Discussion of the drivers and barriers for market growth.

– Analysis of licensing and co-development deals occurring in the hepatitis C market.

Reasons to buy

– Understand the different types of hepatitis C therapies and how treatment varies by genotype.

– Understand the treatment algorithms and guidelines related to hepatitis C, how they are anticipated to change during the forecast period and where opportunities and unmet needs lie.

– Understand the vast Scope of the pipeline, including which molecule types and mechanisms of action are most prominent.

– Observe trends in clinical trial duration and size as clinical phase and molecule type varies. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for hepatitis C therapeutics.

– Observe the shift in clinical trial endpoints with each clinical Phase, and use this data to potentially influence any future developmental programs. Additionally, understand the trends in enrolment by patient genotype.

– Assess the potential clinical and commercial impact of current late-stage pipeline molecules and the points of opportunity which remain to be capitalized upon.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Ovarian Cancer Therapeutics in Major Developed Market Analysis and Research Report 2019: Radiant Insights, Inc

GBI Research, has released the pharma report -“Ovarian Cancer Therapeutics in Major Developed Markets to 2020 – Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies”.

The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/ovarian-cancer-therapeutics-in-major-developed-markets-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies

However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor.

There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS.

In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS – olaparib, Vynfinit and trebananib, will be approved in this territory.

However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA. In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period.

As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020.

Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase.

There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for pancreatic cancer. The report covers and includes –

– A brief introduction to ovarian cancer, including the disease’s pathogenesis, risk factors and diagnosis.

– In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the disease treatment algorithm. This includes a heat map comparing the drug combination in terms of safety and efficacy.

– Comprehensive review of the pipeline for ovarian cancer therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.

– Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.

– Multi-scenario forecast data of the market to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.

– Discussion of the drivers and barriers for market growth.

– An in-depth analysis of licensing and co-development deals involving drugs indicated in ovarian cancer, including an in-depth outline of the key deals.

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to –

– Understanding the efficacy and safety of the current monotherapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm.

– Understand the key signalling pathways and molecular targets currently inder investigation in drug development for ovarian cancer

– Understand the vast Scope of the pipeline, including which molecule types and mechanisms of action are prominent.

– Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic cancer therapeutics.

– Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ovarian cancer therapeutics market.

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Global Insulin Delivery Devices Market Size, Growth and Forecast Report 2019: Radiant Insights, Inc

GBI Research’s report, “Insulin Delivery Devices Market to 2019 – Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers” examines the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories.

It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important mergers and acquisitions.

For more information kindly visit: http://www.radiantinsights.com/research/insulin-delivery-devices-market-to-2019-simplified-pump-solutions-and-low-cost-pens-represent-distinct-regional-growth-drivers

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

– The markets of 12 key geographies are covered: US, Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil.

– Information on market size for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories.

– Annual market revenue data forecast to 2019 and company share data for 2012.

– Qualitative analysis of key trends in the insulin delivery devices market.

– Information on the competitive landscape and the leading technologies of key players: Novo Nordisk, Medtronic, Sanofi, Eli Lilly, Becton, Dickinson and Company, Animas, Insulet, F. Hoffmann-La Roche, Abbott Laboratories.

– Information on reimbursement trends and market access for key countries.

Reasons to buy

– Develop business strategies by understanding the trends and developments driving the global insulin delivery devices market.

– Design and enhance your product development, marketing, and sales strategies.

– Exploit merger and acquisition opportunities by identifying the market players with the most innovative pipelines.

– Develop market-entry and market-expansion strategies.

– Identify the key players best positioned to take advantage of the emerging market opportunities.

– Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.

– Identify, understand and capitalize on the next big thing in the insulin delivery devices market landscape.

– Make more informed business decisions from insightful and in-depth analysis of the global insulin delivery devices market and the factors shaping it.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Pancreatic Adenocarcinoma Therapeutics in Major Developed Market Research Report 2019: Radiant Insights, Inc

GBI Research, the leading business intelligence provider, has released its latest research,’Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 – Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant’, which provides in-depth analysis of pancreatic adenocarcinoma market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

Access This Full Report @ http://www.radiantinsights.com/research/pancreatic-adenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-shows-diversity-of-novel-targets-though-commercial-impact-remains-distant

The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. These include the impact of the drugs approved in the forecast period, but also the increase in the prevalence of the disease and minor improvements in diagnostics that result in more patients being eligible for pharmacological.

 

Scope

– A brief introduction to pancreatic adenocarcinoma, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.

– In-depth analysis of drugs available for the treatment of pancreatic adenocarcinoma, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.

– Comprehensive review of the pipeline for pancreatic adenocarcinoma therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.

– Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.

– Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.

– Discussion of the drivers and barriers for market growth.

– Discussion of the licensing and co-development deals landscape in pancreatic adenocarcinoma, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.

Reasons to buy

– Understand the vast Scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent.

– Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic adenocarcinoma therapeutics.

– Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the pancreatic adenocarcinoma therapeutics market.

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Market Research Report – Pain-Identifying and Commercializing First-in-Class Innovation: Radiant Insights, Inc

Large and Innovative Pipeline

The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation.

This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID).

Browse Full Report With TOC @ http://www.radiantinsights.com/research/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation

However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

Despite being mostly distributed in the early stages of development, first-in-class innovation is particularly concentrated on novel molecular targets that are aligned to the central sensitization associated with neuropathic pain, which is arguably the most debilitating and difficult-to-treat type of chronic pain. This gives them the potential to transform the future market by expanding the range of drug classes.

 

Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents

Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibit distinct underlying etiologies and pathophysiologies. While technological advances and extensive research efforts have furthered the understanding of these complex underpinnings, gaps remain. However, these insights have translated into the expanding pool of novel therapeutic targets, as reflected by the highly innovative pipeline. GBI Research’s proprietary analysis shows that early-stage, first-in-class programs exhibit a higher level of diversity with respect to novel therapeutic targets. The significant diversity in terms of targets is a reflection of the complex underpinnings of distinct pain subtypes. Although the pipeline continues to feature established therapies, the range of mechanisms of action employed by novel compounds is extremely diverse, with the vast majority residing in the Preclinical stage.

This innovation and diversity is maintained throughout the pipeline from early- to late-stage development, although the degree of innovation diminishes from Phase II. Additionally, although NSAIDs and opioids remain the cornerstone of pain treatment, GBI Research analysis indicates a shift towards pain subtypes that are more difficult to treat.

Encouragingly, these first-in-class compounds often target molecules which are strongly implicated in pain and its associated signaling pathways. Although there are significant differentiations in the scientific rationale and clinical prospects across these first-in-class products, the majority demonstrate significant Preclinical evidence and alignment to molecular pathophysiological changes.

In addition, GBI Research’s comprehensive and complementary analysis of granted patents highlighted a significant number of first-in-class product technologies, many of which have not been identified in the pain product pipelines or even in pipelines across the industry.

The distribution of these products across the molecular target superfamilies and families highlighted that they predominantly align with the proportional distribution observed across the pain pipeline, with G-protein-coupled receptors and enzymes inhibitors constituting the two major categories. However, an array of novel molecular targets within those groups has been identified, which do not present in any pipeline or marketed products across the industry. A significant degree of innovation has also been identified in other molecular target categories.

Active Deals Landscape with Numerous Investment Opportunities

The pain deals landscape has been highly active over the past eight years, with 261 licensing deals and 112 co-development deals. However, despite high levels of investment activity, deals for first-in-class products have been relatively rare.

Overall, more than 50% of deals involving first-in-class targets were settled in the early stages of development, which is a striking contrast with non-first-in-class products, which are more frequently entered into deals in the later stages of development. This reflects companies’ willingness to invest despite the high-risk profile of first-in-class products.

With 107 first-in-class products available for strategic consolidations, a wide variety of investment opportunities are available for licensing deals or co-development deals in pain. This will be encouraged by the growing unmet need for chronic pain therapies, and an increased understanding of the distinct underlying pathophysiologies of distinct pain sub-types, allowed by technological advances. Among these, some first-in-class products have demonstrated promising Preclinical evidence and have significant potential to become game-changing products, representing high-reward investments.

 

Scope

The report covers and includes –

– A brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms

– The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline

– A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target

– Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets

– Assessment of the licensing and co-development deal landscape for pain therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to –

– Understand the focal shifts in molecular targets in the pain therapeutics pipeline

– Understand the distribution of pipeline programs by phase of development, molecule type and molecular target

– Access a scientific and clinical analysis of first-in-class developmental programs for pain, benchmarked against non-first-in-class targets.

– Access a list of the first-in-class therapies potentially open to deal-making opportunities

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Market Analysis: Liver Cancer-Identifying and Commercializing First-in-Class Innovation By Radiant Insights, Inc

Large and Diverse Pipeline

The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market.

The contrast between the market and pipeline is vast. Analysis showed that the market contains 70 products, the majority of which are generic formulations of chemotherapies that are not frequently used in treatment, particularly in advanced-stage patients. Nexavar (sorafenib) is the dominant therapeutic on the market, and is also the only targeted therapy that is in regular use for advanced-stage liver cancer patients.

 

Read Complete Report with TOC @ http://www.radiantinsights.com/research/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation

However, pipeline analysis revealed that targeted therapies aimed at the underlying oncogenic signaling pathways are under much greater focus in the pipeline than in the market. The success of targeted therapies across the oncology market as a whole implies that the diversity and innovation in the pipeline is a promising sign, with products currently in development having the potential to transform and improve the relatively open liver cancer market.

Alignment of First-in-Class Molecular Targets with Disease Causation

The liver cancer pipeline is showing signs of adapting to the increasing understanding of aberrant signaling pathways and causes of liver cancer. A large portion of pipeline products target components of known dysfunctional signaling pathways, such as Wnt/ß–catenin signaling, which is commonly mutated in liver cancer tumor samples.

By aligning the treatment with specific disease-causing features, the damaging off-target cytotoxic effects of treatment can be reduced, resulting in safer and more efficacious therapies.

GBI Research’s analysis identified substantial variation in the alignment of first-in-class products to underlying dysfunctional signaling at protein and genetic level. The first-in-class products were compared in an in-depth analysis using various parameters to measure the potential of each target, with the most promising targets being further substantiated by published clinical and scientific evidence.

Results of the analysis suggested that first-in-class status is not a feature that, in its own right, will create a successful product. However, there are a large number of first-in-class products backed by clinical and Preclinical data that are exciting future prospects for the liver cancer market.

 

Analysis of Patent Data

The report features an analysis of granted patent applications in the liver cancer market, which was used as an indication of innovation at the earliest stage of product development. Patent analysis provides an insight into the pre-developmental landscape, and identifies long-term future trends within a disease market.

In liver cancer, the trend in patent applications in terms of predominant molecular targets reflects the pipeline landscape, suggesting that liver cancer therapeutics will continue to target key oncogenic signaling pathways in the long term.

The frequency at which companies apply for patents within the market helps to identify companies that are trying to establish themselves or increase their liver cancer market share. This information identifies not only potential competitors, but also companies that may seek strategic partnerships to enter drug development.

 

First-in-Class Products in Licensing and Co-Development Deals

The deals landscape for liver cancer has been relatively active in recent years, with 62 licensing deals and 23 co-development deals between 2006 and 2014. However, the number pertaining to first-in-class products is very low.

A comparative analysis of the deals revealed that first-in-class products have the potential to command substantially higher deal values than non-first-in-class products, which is a reflection of their market potential and importance.

A total of 68 first-in-class products that are currently in development have not yet been entered into a licensing or co-development deal. In a transforming market that will favor innovative, targeted therapies with a strong clinical record, there are numerous opportunities for strategic alliances to bolster a first-in-class portfolio or fund clinical development. Although not all are aligned to disease-causing signaling pathways, many are supported by robust scientific and clinical data, making them attractive prospects as both therapeutics and investment opportunities.

Scope

The report includes –

– A brief introduction to liver cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms

– Coverage of the changing molecular target landscape and particular points of innovation in the pipeline

– A comprehensive review of the pipeline for first-in-class therapies, analyzed by stage of development, molecule type and molecular target

– Analysis of patent trends and patent families in liver cancer

– Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews of novel molecular targets

– Industry-wide analysis of first-in-class deals compared to non-first-in-class deals

– An assessment of the licensing and co-development deal landscape for liver cancer therapies, and benchmarking of deals comparing first-in-class and non-first-in-class-products

Reasons to buy

The report will enable business development and enable marketing executives to strategize their product launches by allowing them to –

– Understand the focal shifts in molecular targets in the liver cancer pipeline

– Understand the distribution of pipeline programs by phase of development, molecule type and molecular target

– Understand the patent trends in liver cancer and what this means for long-term innovation

– Access a scientific and clinical analysis of first-in-class developmental programs for liver cancer, benchmarked against non-first-in-class targets

– Assess the valuations of licensed and co-developed liver cancer treatments

– Access a list of the first-in-class therapies potentially open to deal-making opportunities.

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/